ISORAY, INC. (NYSEMKT:ISR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
This Amendment No. 1 to Form 8-K amends the Current Report on Form 8-K filed by IsoRay, Inc. (the “Company”) on January 17, 2017 (the “Original Report”), to disclose that Matthew Branson was appointed as both principal financial officer and principal accounting officer. Except as provided herein, the disclosures in the Original Report remain unchanged.
Matthew Branson was appointed both Principal Financial Officer and Principal Accounting Officer, as such terms are defined in SEC regulations, effective January 17, 2017, to serve at the discretion of the Board. Mr. Branson was not appointed to any arrangement or understanding between Mr. Branson and any other person. In connection with Mr. Branson’s appointment as Principal Financial Officer and Principal Accounting Officer, the Company did not enter into or materially amend any plan, contract, or arrangement that Mr. Branson will participate in as Principal Financial Officer and Principal Accounting Officer. Additional information about Mr. Branson and his background is included in the Original Report.
About ISORAY, INC. (NYSEMKT:ISR)
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. ISORAY, INC. (NYSEMKT:ISR) Recent Trading Information
ISORAY, INC. (NYSEMKT:ISR) closed its last trading session up +0.007 at 0.592 with 89,006 shares trading hands.